ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: L05 • ACR Convergence 2024

    Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels

    Christian Schwabe1, Orit Cohen Barak2, Alexandra Cole3, Hadar Reuveni2, Liron Shelev2, Liora Blinder-Haddad2 and Nicola Dalbeth4, 1NZCR, Auckland, New Zealand, 2Protalix Ltd, Karmiel, Israel, 3NZCR, Christchurch, New Zealand, 4University of Auckland, Auckland, New Zealand

    Background/Purpose: PEGylated uricases have already demonstrated therapeutic modality in the treatment of refractory gout patients. PRX-115 is a recombinant homotetrameric uricase enzyme, produced from Candida…
  • Abstract Number: L09 • ACR Convergence 2024

    Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis

    Hermine Brunner1, Caifeng Li2, Kogie Chinniah3, Yosef Uziel4, Olga Synoverska5, Sujata Sawhney6, Inmaculada Calvo Penades7, Ingrid Clara Louw8, Meiping Lu9, Pooja Nikunj Patel10, Pamela F. Weiss11, Cheng Chang12, Ivana Vranic13, Shixue Liu14, Annette Diehl15, Jose L. Rivas16, Carol A. Connell17, Gary G. Koch18, Alberto Martini19, Daniel J. Lovell1, Nicolino Ruperto20 and the PRINTO and PRCSG investigators, 1Cincinnati Children’s Hospital Medical Center, and University of Cincinnati, Cincinnati, OH, 2Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Bejing, China, 3Department of Paediatrics and Child Health, University of Kwa-Zulu, and Enhancing Care Foundation, Durban, South Africa, 4Pedriatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center and Israel Tel Aviv University School of Medicine, Kfar Saba, Israel, 5Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine, 6Sir Ganga Ram Hospital, New Delhi, India, 7Hospital Universitario y Politécnico La Fe, Valencia, Spain, 8Panorama Medical Centre, Cape Town, South Africa, 9Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, 10Ann & Robert H. Lurie Children’s Hospital of Chicago; Northwestern University School of Medicine, Chicago, IL, 11Division of Rheumatology, Children's Hospital of Philadelphia, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 12Pfizer Inc, New York, NY, 13Pfizer Ltd, Tadworth, United Kingdom, 14Pfizer Inc, Shanghai, China, 15Pfizer Inc, Collegeville, PA, 16Pfizer SLU, Madrid, Spain, 17Pfizer Inc, Groton, CT, 18University of North Carolina at Chapel Hill, Chapel Hill, NC, 19University of Genoa, Genoa, Italy, 20Università Milano Bicocca, Milano, and IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy

    Background/Purpose: Tofacitinib (TOF) has been shown to be efficacious in the treatment of polyarticular course JIA, including systemic JIA (sJIA) without active systemic features. Here…
  • Abstract Number: L10 • ACR Convergence 2024

    Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study

    John Tesser1, Joshua June2, Pendleton Wickersham3, Jane Box4, Guillermo Valenzuela5, Angela Crowley6, Nikila Kumar7, Norman Gaylis8, Gordan Lam9, David Ridley10, Gineth Paola Pinto-Patarroyo11 and David Chernoff12, 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2Great Lakes Center of Rheumatology, Lansing, MI, 3Arthritis Associates PA, San Antonio, TX, 4DJL Clinical Research, PLLC, Charlotte, NC, 5Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, 6Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, 7Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, 8Arthritis & Rheumatic Disease Specialties, Aventura, FL, 9Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, 10St. Paul Rheumatology, Eagan, MN, 11Annapolis Rheumatology, Fairfax, VA, 12SetPoint Medical, Sausalito, CA

    Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
  • Abstract Number: L16 • ACR Convergence 2024

    Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial

    Megan Clowse1, David Isenberg2, Joan Merrill3, Thomas Dörner4, Michelle Petri5, Edward Vital6, Eric Morand7, Teri Jimenez8, Stephen Brookes9, Janine Gaiha-Rohrbach10, Christophe Martin11, Annette Nelde12 and Christian Stach13, 1Division of Rheumatology and Immunology, Duke University, Durham, NC, 2Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, 5Johns Hopkins University School of Medicine, Baltimore, MD, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 8UCB, Raleigh, NC, 9Biogen, Maidenhead, United Kingdom, 10Biogen, Cambridge, MA, 11UCB, Slough, United Kingdom, 12Biogen, Baar, Switzerland, 13UCB, Monheim am Rhein, Germany

    Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…
  • Abstract Number: 0180 • ACR Convergence 2024

    Collaborative Solutions to Lupus Trial Challenges for Underrepresented Participant Recruitment & Engagement: Perspectives from the Lupus Clinical Investigators Network (LuCIN)

    Brandon Jackson1, Maria Dall'Era2, Saira Sheikh3, Xueting Zhang4, Taylor Irons5, Claire Finney6, Taylor Adjei7, Jennifer Meriwether7, Caroline Donovan8, Carla Menezes9 and Stacie Bell10, 1Lupus Research Alliance / Lupus Therapeutics, Miami, FL, 2UCSF, Corte Madera, CA, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, 4Weill Cornell, New York, NY, 5Lupus Research Alliance / Lupus Therapeutics, Houston, 6Lupus Research Alliance / Lupus Therapeutics, Birmingham, AL, 7Lupus Research Alliance / Lupus Therapeutics, New York, NY, 8Lupus Research Alliance / Lupus Therapeutics, Arlington, VA, 9Lupus Research Alliance / Lupus Therapeutics, Brooklyn, NY, 10Lupus Therapeutics, Lakewood, CO

    Background/Purpose: Racial and ethnic minority groups face higher lupus prevalence and severity and remain inadequately represented in lupus clinical trials. Lupus Therapeutics, the clinical affiliate…
  • Abstract Number: 0526 • ACR Convergence 2024

    Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study

    Narendra Maharaj1, Dharma rao Uppada2, Naveen Reddy MAREDDY1, Pramod Reddy Pundra1, Anastas Batalov3, Delina Ivanova4, nedyalka staykova5, Asta Baranauskaite6 and Laila Hassan7, 1Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, India, 2Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, 3Medical University of Plovdiv, Medical Faculty, University Hospital "Kaspela", Clinic of Rheumatology, Plovdiv 4000, Bulgaria, Plovdiv, Bulgaria, 4Diagnostic and Consulting Center Aleksandrovska EOOD Sofia 1431, Bulgaria, Sofia, Bulgaria, 5Outpatient Clinic for Specialized Medical Help – Medical Center Kuchuk Paris OOD; Plovdiv 4004, Bulgaria, plovdiv, Bulgaria, 6Hospital of Lithuanian University of Health Sciences Kauno Klinikos, LT-50161, Lithuania, Kaunas, Lithuania, 711914 Astoria Blvd. Ste. 330, Houston TX 77089 United States, Houston, TX

    Background/Purpose: To assess immunogenicity and safety in patients with active rheumatoid arthritis (RA) transitioning from US-Rituximab (RP) or EU-Rituximab (RMP) to DRL_RI (proposed rituximab biosimilar),…
  • Abstract Number: 0670 • ACR Convergence 2024

    A Randomized, Open-Label, Phase III Trial Comparing Efficacy and Safety of Intravenous Cyclophosphamide, Mycophenolate Mofetil, or Tacrolimus as Induction Therapy in Lupus Nephritis

    Alekhya Amudalapalli, Ashlesha Shukla, Abhichandra Maddineni, Sandeep Nagar, Sudhish Gadde, Harish BV, Rashmi Ranjan Sahoo and Pradeepta Sekhar Patro, IMS and SUM Hospital, Bhubaneswar, India

    Background/Purpose: The optimal treatment for lupus nephritis is challenging due to its heterogeneity and the lack of prognostic factors favoring one immunosuppressive drug over another.…
  • Abstract Number: 1030 • ACR Convergence 2024

    Diversity in Axial Spondyloarthritis Drug Trials: Examining Enrollment by Sex, Race, Ethnicity and Geographic Region

    Mathieu Choufani1, Wissam Ghusn2 and Joerg Ermann3, 1Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, 2Department of Internal Medicine, Boston Medical Center, Boston, MA, 3Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: While axial spondyloarthritis (AxSpA) was historically perceived as a "white man's disease", it is now appreciated as a condition that can affect individuals of…
  • Abstract Number: 1392 • ACR Convergence 2024

    Safety and Efficacy of Upadacitinib (UPA) in Japanese Patients with Rheumatoid Arthritis (RA) and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-SUNRISE Study

    Hideto Kameda1, Tsutomu Takeuchi2, Kunihiro Yamaoka3, Motohiro Oribe4, Mitsuhiro Kawano5, Masayuki Yokoyama6, Yuko Konishi6, Sumi Chonan6, Sara Penn7, Heidi S Camp7 and Yoshiya Tanaka8, 1Toho University, Tokyo, Japan, 2Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 3Kitasato University School of Medicine, Kanagawa, Japan, 4Oribe Clinic of Rheumatism and Medicine, Oita, Japan, 5Kanazawa Medical University, Ishikawa, Japan, 6AbbVie GK, Tokyo, Japan, 7AbbVie, North Chicago, IL, 8Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan

    Background/Purpose: To evaluate the efficacy and safety of UPA in Japanese RA patients (pts) up to 5 yrs in a long term extension (LTE) of…
  • Abstract Number: 1494 • ACR Convergence 2024

    Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab

    Ioannis Parodis1, Julius Lindblom2, Alexandre Tsoi3, Dionysis Nikolopoulos4 and Lorenzo Beretta5, 1Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Karolinska Institute, Stockholm, Sweden, 4Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 5Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy

    Background/Purpose: The efficacy of belimumab in treating SLE has been demonstrated in several phase 3 randomized clinical trials (RCTs). These trials showed belimumab efficacy on…
  • Abstract Number: 1759 • ACR Convergence 2024

    Predictors of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis Receiving IL-17A Inhibitor or TNF Inhibitor Therapy over 2 Years: A Post Hoc Analysis of a Phase IIIb Study

    Denis Poddubnyy1, Juergen Braun2, Pedro M Machado3, Victoria Navarro Compán4, Lianne S Gensler5, Kay Geert Hermann6, Erhard Quebe-Fehling7, Christelle C Pieterse8, Aimee Readie9, Corine Gaillez7 and Xenofon Baraliakos10, 1Charite-Universitatsmedizin Berlin, Berlin, Germany, 2Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, 3Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, 4La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 5Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 6Charite Medical School, Berlin, Germany, 7Novartis Pharma AG, Basel, Switzerland, 8Syneos Health, Amsterdam, Netherlands, 9Novartis Pharmaceuticals Corporation, East Hanover, NJ, 10Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany

    Background/Purpose: Previous studies have identified predictors of radiographic spinal progression in patients with axial spondyloarthritis (axSpA). In this post hoc analysis of the SURPASS study…
  • Abstract Number: 2102 • ACR Convergence 2024

    Unraveling Knee Osteoarthritis Subtypes: Differential Effect of Oral Salmon Calcitonin Treatment

    Monica Hannani1, Peder Frederiksen2, Morten Karsdal2, Asger Reinstrup Bihlet3, Jaume Bacardit4, Anne-Christine Bay-Jensen2 and Christian Thudium2, 1Nordic Bioscience & University of Copenhagen, Herlev, Denmark, 2Nordic Bioscience, Herlev, Denmark, 3NBCD A/S, Soeborg, Denmark, 4School of Computing, Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Osteoarthritis (OA) patients are to this day left without effective treatment options. Despite different etiologies, trials designs do not account for the substantial heterogeneity…
  • Abstract Number: 2370 • ACR Convergence 2024

    Redefining Clinical Trial Inclusion Criteria Using Quality of Life in Cutaneous Lupus Erythematosus

    Daniella Faden1, lillian Xie2, Caroline Stone1, Lais Lopes Almeida Gomes1, Ahmed Eldaboush1, Cristina Ricco2, Rui Feng2 and Victoria Werth3, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, 3University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Regulatory guidance on endpoint measures for disease activity in cutaneous lupus erythematosus (CLE) patients is essential to improve therapies. CLE profoundly impacts quality of…
  • Abstract Number: 0200 • ACR Convergence 2024

    Evaluating the Effectiveness of Educational Initiatives on Recruiting Underrepresented Participants into SLE Clinical Trials

    Maria Bacalao1, Marie Maitre2 and Shivani Kottur3, 1UT Southwestern, Dallas, TX, 2Parkland Hospital, Dallas, TX, 3UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: Healthcare disparities in SLE clinical trials are well known, with minoritized individuals facing more significant SLE morbidity and mortality, while being underrepresented in randomized…
  • Abstract Number: 0533 • ACR Convergence 2024

    Using Adalimumab Serum Concentration to Choose a Subsequent DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (ADDORA-switch): Results of a Blinded Randomized Test Treatment Trial

    Maike Wientjes1, Sadaf Atiqi2, Gertjan Wolbink3, Michael Nurmohamed4, Maarten Boers5, Femke Hooijberg2, Theo Rispens6, Annick De Vries6, Floris Loeff6, Ronald Van Vollenhoven7, Sofia Ramiro8, Noortje van Herwaarden9, Bart van den Bemt10 and Alfons den Broeder1, 1Sint Maartenskliniek, Ubbergen, Netherlands, 2Reade, Amsterdam, Netherlands, 3Reade and Sanquin Diagnostic Services, Amsterdam, Netherlands, 4Reade and Amsterdam UMC, Kortenhoef, Netherlands, 5Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, 6Sanquin Diagnostic Services, Amsterdam, Netherlands, 7Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, 8Leiden University Medical Center, Bunde, Netherlands, 9Sint Maartenskliniek, Nijmegen, Netherlands, 10Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands

    Background/Purpose: Adalimumab is an effective and safe treatment for RA, however a substantial proportion of RA patients discontinue its use due to inefficacy. Upon failure,…
  • 1
  • 2
  • 3
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology